The Intrathecal Morphine for Nephrectomy (EMPON)
Primary Purpose
Renal Cell Carcinoma
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
The intrathecal morphine injection
The intravenous patient-controlled analgesia
Demerol on demand
Sponsored by
About this trial
This is an interventional treatment trial for Renal Cell Carcinoma focused on measuring Injection, Spinal, Morphine, Analgesia, Patient-Controlled, Pain, Postoperative, Combined Modality Therapy, Nephrectomy
Eligibility Criteria
Inclusion Criteria:
- Patients scheduled for the open nephrectomy
Exclusion Criteria:
- Patients with renal insufficiency
- Patients with coagulopathy
- History of any neurologic disorder
- History of recent infection in 2 weeks
- History of drug abuse
- Patients who cannot understand the usage of th intravenous patient-controlled analgesia
- Patients using opioids due to the chronic pain
Sites / Locations
- Seoul National University of Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
The ITM group
The IV-PCA group
Arm Description
The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
Outcomes
Primary Outcome Measures
The evaluation of pain at 24 hours after surgery
The doctor blinded to the investigation will visit patients. The pain will be assessed at rest and at coughing using visual analogue scale.
Secondary Outcome Measures
The consumption of analgesics
The total amount of opioids (IV morphine) used for 24 hours after surgery will be recorded and compared.
The consumption of intraoperative opioids
The total amount of intraoperative opioids (IV remifentanil) will be recorded and compared.
The side effects of opioids after surgery
Any side effects of opioids including nausea, vomiting, dizziness, sedation, headache, pruritus and respiratory depression will be recorded.
Full Information
NCT ID
NCT01997788
First Posted
September 10, 2013
Last Updated
July 1, 2015
Sponsor
Seoul National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01997788
Brief Title
The Intrathecal Morphine for Nephrectomy
Acronym
EMPON
Official Title
The Efficacy of Intrathecal Morphine in Patients Undergoing Open Nephrectomy
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
August 2013 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
October 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To evaluate the efficacy and the safety of the intrathecal morphine injection in the open nephrectomy.
Detailed Description
The open nephrectomy is the treatment of choice for live donor kidney transplantation and renal cell carcinoma. The incision for the nephrectomy causes severe postoperative pain. A single dose of intrathecal morphine(ITM) has been used for the postoperative pain of prostatectomy, transurethral resection of the prostate and hepatectomy. The effect of ITM for open nephrectomy has not been studied. Therefore, this prospective, randomized study will evaluate the efficacy and safety of a single 50 mcg dose of ITM added to intravenous patient controlled analgesia(IV-PCA), comparing to IV-PCA alone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Cell Carcinoma
Keywords
Injection, Spinal, Morphine, Analgesia, Patient-Controlled, Pain, Postoperative, Combined Modality Therapy, Nephrectomy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
The ITM group
Arm Type
Experimental
Arm Description
The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
Arm Title
The IV-PCA group
Arm Type
Placebo Comparator
Arm Description
The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
Intervention Type
Drug
Intervention Name(s)
The intrathecal morphine injection
Intervention Description
A single injection of morphine intrathecally
Intervention Type
Drug
Intervention Name(s)
The intravenous patient-controlled analgesia
Intervention Description
The intravenous injection of morphine using the patient-controlled analgesia machine
Intervention Type
Drug
Intervention Name(s)
Demerol on demand
Intervention Description
Demerol 25 mg intravenously when pain scores more than 5.
Primary Outcome Measure Information:
Title
The evaluation of pain at 24 hours after surgery
Description
The doctor blinded to the investigation will visit patients. The pain will be assessed at rest and at coughing using visual analogue scale.
Time Frame
at postoperatively 24 hours
Secondary Outcome Measure Information:
Title
The consumption of analgesics
Description
The total amount of opioids (IV morphine) used for 24 hours after surgery will be recorded and compared.
Time Frame
at postoperatively 24 hours
Title
The consumption of intraoperative opioids
Description
The total amount of intraoperative opioids (IV remifentanil) will be recorded and compared.
Time Frame
From the induction of anesthesia till the emergence of anesthesia, an expected average of 4 hours
Title
The side effects of opioids after surgery
Description
Any side effects of opioids including nausea, vomiting, dizziness, sedation, headache, pruritus and respiratory depression will be recorded.
Time Frame
During 72 hours after the end of surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients scheduled for the open nephrectomy
Exclusion Criteria:
Patients with renal insufficiency
Patients with coagulopathy
History of any neurologic disorder
History of recent infection in 2 weeks
History of drug abuse
Patients who cannot understand the usage of th intravenous patient-controlled analgesia
Patients using opioids due to the chronic pain
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deok-Man Hong, PhD
Organizational Affiliation
Seoul National University of Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Seoul National University of Hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
The Intrathecal Morphine for Nephrectomy
We'll reach out to this number within 24 hrs